Sulodexide is a glycosaminoglycan, primarily composed of heparin and dermatan sulfate, and is used therapeutically for its anticoagulant and anti-inflammatory properties. It is often employed in the treatment of various vascular disorders, including chronic venous insufficiency and peripheral arterial disease. Sulodexide exhibits a unique mechanism of action by enhancing the activity of antithrombin III, which inhibits thrombin and factor Xa, thereby reducing blood clot formation. Additionally, it promotes endothelial cell function and has a protective effect on blood vessels. The substance is typically administered via subcutaneous injection and is characterized by its relatively low molecular weight, which contributes to its bioavailability and efficacy. Sulodexide is generally well-tolerated, with a safety profile that includes mild side effects such as gastrointestinal disturbances or local reactions at the injection site. Its pharmacokinetics involve rapid absorption and a short half-life, necessitating regular dosing for optimal therapeutic effects. Overall, sulodexide represents a valuable option in the management of thromboembolic conditions and vascular health.

SULODEXIDE

57821-29-1: Sulodexide is a glycosaminoglycan, primarily composed of heparin and dermatan sulfate, and is used therapeutically for its anticoagulant and anti-inflammatory properties. It is often employed in the treatment of various vascular disorders, including chronic venous insufficiency and peripheral arterial disease. Sulodexide exhibits a unique mechanism of action by enhancing the activity of antithrombin III, which inhibits thrombin and factor Xa, thereby reducing blood clot formation. Additionally, it promotes endothelial cell function and has a protective effect on blood vessels. The substance is typically administered via subcutaneous injection and is characterized by its relatively low molecular weight, which contributes to its bioavailability and efficacy. Sulodexide is generally well-tolerated, with a safety profile that includes mild side effects such as gastrointestinal disturbances or local reactions at the injection site. Its pharmacokinetics involve rapid absorption and a short half-life, necessitating regular dosing for optimal therapeutic effects. Overall, sulodexide represents a valuable option in the management of thromboembolic conditions and vascular health.

<p>Sulodexide is an orally administered combination of glycosaminoglycans, consisting of low molecular weight heparin (80%) and dermatan sulfate (20%). It demonstrates antithrombotic properties by interacting with antithrombin III (AT III) and heparin cofactor II (HC II), and by inhibiting thrombin formation. Additionally, sulodexide enhances profibrinolytic activity by releasing tissue plasminogen activator (tPA). It also offers endothelial protection, possesses anti-inflammatory effects, and alleviates chronic venous disease.</p>

CAS 57821-29-1

SULODEXIDE

Sulodexide

Ref: TM-T88323